Drug developer Generate Biomedicines raises $400 million in US IPO (February 26, 2026) by Reuters Founded by Flagship in 2018, Generate Biomedicines uses AI-driven technology to move beyond traditional trial-and-error drug discovery and develop new protein-based therapies, with its pipeline centered on immunology and oncology. Generate’s lead drug candidate for severe asthma, GB-0895, is currently in a late-stage trial, with

Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics (Ingelheim, Germany, Oxford, UK, and Boston, USA, Feb 26, 2026) by Linda Ruckel and Dr Reinhard Malin. The preclinical, small molecule program offers a potential first-in-class, oral, precision immunometabolic approach to modulating disease-driving immune cells Deal includes upfront and milestone payments to Sitryx totaling over US $500

Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo (Jan 27, 2026) by Reuters. BERLIN, Jan 27 (Reuters) – Roche’s experimental obesity drug, which works in a similar way to Eli Lilly’s Zepbound, produced as much as 22.5% weight loss in a mid-stage trial, underpinning the Swiss drugmaker’s efforts to catch up with

Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research (Dec 15, 2025) by Reuters. Adaptive said it will earn up to $890 million for the rheumatoid arthritis asset, including upfront fees and milestone payments tied to research progress, product development, and sales. Pfizer will use Adaptive’s technology to analyze immune cells from rheumatoid arthritis patients

Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech (Dec 9, 2025) by James Waldron . What we do know is that Novartis will hand over $55 million, spread across an upfront cash payment, an equity investment and additional R&D funding. Down the line, Relation is eligible to receive preclinical, development, regulatory and commercial sales milestones that could reach $1.7

Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies (Oct 22, 2025) by Darren Incorvaia. Regeneron is buying in to Modex Therapeutics’ next-generation antibody platform with a $7 million upfront payment and a total potential deal value exceeding $1 billion. The New York-based biopharma will provide binders that ModeX will pair with its platform to fashion new multispecific antibodies

Novartis goes big for neuroscience with $12B deal for late-stage dystrophy biotech Avidity (Oct 22, 2025) by James Waldron . Almost a year after buying Kate Therapeutics, Novartis has scooped up another San Diego-based muscle dystrophy biotech in one of the biggest acquisitions of 2025 so far. The Swiss pharma is paying $12 billion for Avidity Biosciences and its three late-stage antibody-oligonucleotide

Takeda turns to AI drug designer for $1B biobucks deal after whittling down R&D focus (Oct 22, 2025) by Nick Paul Taylor. Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes (PDF) $10.2 billion in milestones, puts the biologics at the center of Takeda’s efforts to establish growth drivers for the

Takeda turns to AI drug designer for $1B biobucks deal after whittling down R&D focus (Oct 14, 2025) by Darren Incorvaia. After walking away from cell therapy and narrowing its focus to just three modalities, Takeda is doubling down on its remaining strategic commitment by reupping a pact with AI drug designer Nabla Bio. Nabla, a Harvard spinout from the

Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional payments for other indications; includes contingent R&D investment, tiered sales royalties, and a portion of investment to